Trademark Overview
On Wednesday, November 1, 2023, a trademark application was filed for RELZIMFI with the United States Patent and Trademark Office. The USPTO has given the RELZIMFI trademark a serial number of 98250654. The federal status of this trademark filing is NOTICE OF ALLOWANCE - ISSUED as of Tuesday, September 10, 2024. This trademark is owned by Eli Lilly and Company. The RELZIMFI trademark is filed in the Pharmaceutical Products category with the following description:
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, hearing loss, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative co...
